Form: 4

Statement of changes in beneficial ownership of securities

March 29, 2007

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Eichler David A
   2. Issuer Name and Ticker or Trading Symbol
eXegenics Inc [EXEG] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
625 AVENUE OF THE AMERICAS		 3. Date of Earliest Transaction (Month/Day/Year)
03/27/2007
(Street)

NEW YORK, NY 10011		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Convertible Preferred Stock $ 0 03/27/2007   J(1)   90,815     (2)   (2) Common Stock 9,081,500 $ 0 90,815 I See Footnote (3)
Warrant (Right to Buy) $ 0.002 03/27/2007   J(1)   1,135,188     (4) 03/27/2017 Common Stock 1,135,188 $ 0 1,135,188 I See Footnote (3)
Warrant(Right to Buy) $ 0.6728 03/27/2007   J(1)   309,737     (4) 03/27/2017 Common Stock 309,737 $ 0 309,737 I See Footnote (3)
Warrant (Right to Buy) $ 0.8473 03/27/2007   J(1)   309,737     (4) 03/27/2017 Common Stock 309,737 $ 0 309,737 I See Footnote (3)
Warrant (Right to Buy) $ 1.0466 03/27/2007   J(1)   309,737     (4) 03/27/2017 Common Stock 309,737 $ 0 309,737 I See Footnote (3)
Stock Option (Right to Buy) $ 0.04 03/27/2007   J(1)   25,947     (5) 11/08/2014 Common Stock 25,947 $ 0 25,947 I See Footnote (3)
Stock Option (Right to Buy) $ 0.04 03/27/2007   J(1)   103,788     (5) 02/15/2015 Common Stock 103,788 $ 0 103,788 I See Footnote (3)
Stock Option (Right to Buy) $ 0.05 03/27/2007   J(1)   155,682     (6) 02/28/2016 Common Stock 155,682 $ 0 155,682 I See Footnote (3)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Eichler David A
625 AVENUE OF THE AMERICAS
NEW YORK, NY 10011		   X      

Signatures

 /s/ David A. Eichler   03/29/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.
(2) These shares are currently exercisable and do not expire.
(3) As Managing Director of Psilos Group Investors II-S, LLC, the General Partner of Psilos Group Partners II SBIC, L.P.
(4) These warrants are currently exercisable.
(5) These options are fully vested.
(6) 56,218.83 of these options are fully vested. The balance will vest monthly until fully vested in December 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.